Avastin (bevacizumab) / Roche - LARVOL DELTA

Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis. (PubMed, Neurosurg Rev) - "High heterogeneity was noted for overall survival (I² = 98.24%), warranting cautious interpretation. This meta-analysis suggests that while Gamma Knife combined with bevacizumab significantly prolongs progression-free survival in patients with recurrent high-grade glioma, it does not confer an overall survival advantage."

Clinical • Journal • Retrospective data • Review • Brain Cancer • Glioma • Malignant Glioma • Oncology • Solid Tumor

Signal Mining and Analysis of Drug-Induced Myelosuppression: A Real-World Study From FAERS. (PubMed, Cancer Control) - "The drugs most frequently linked to DIM included trastuzumab, bevacizumab, venetoclax, methotrexate, and pertuzumab. Additionally, 12 new drug signals were identified that were not labeled for DIM risk, including PERTUZUMAB, SODIUM CHLORIDE, and MESNA, which showed particularly strong or unexpected associations.ConclusionThis study identifies new DIM-related drug signals and emphasizes the need for early detection to improve clinical management and optimize treatment regimens. The findings provide valuable evidence for drug safety monitoring and can help reduce DIM-related risks in cancer treatment."

Journal • Real-world evidence • Breast Cancer • Hematological Disorders • Infectious Disease • Oncology • Solid Tumor

Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. (PubMed, Asian Pac J Cancer Prev) - "LEN was found to be non-inferior to ATE/BEV in terms of OS, PFS, ORR, DCR. However, LEN may be associated with a higher incidence of AEs."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Dermatology • Fatigue • Fibrosis • Gastroenterology • Genetic Disorders • Hepatitis B • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Liver Cancer • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Renal Disease • Solid Tumor

Pancreatic metastasis from cervical cancer: A case report and literature review. (PubMed, Oncol Lett) - "Between January and May 2024, the patient underwent six cycles of paclitaxel/carboplatin/bevacizumab/programmed cell death protein 1 inhibitor therapy followed by IMRT (45 Gy with 55 Gy boost)...As of November 2024, the latest data indicated that the patient was disease-free on pembrolizumab maintenance...In conclusion, there is currently no consensus regarding subsequent treatment plans. Pancreatic metastases originating from cervical cancer are infrequent and necessitate careful consideration along with individualized treatment approaches."

Journal • Cervical Cancer • Cervical Squamous Cell Carcinoma • Gynecology • Obstetrics • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma

Spinal cord metastasis in a long-term survivor of primary malignant glioblastoma: A case report. (PubMed, Oncol Lett) - "For recurrence, she received tumor treating fields and bevacizumab. At 23 months post-surgery, she developed COVID-19 pneumonia treated with dexamethasone, followed by spinal symptoms...Surgical resection and chemoradiotherapy remain the mainstay, while emerging treatments may provide hope for recurrent cases. Supportive care plays a critical role in advanced disease stages."

Journal • Brain Cancer • Glioblastoma • Infectious Disease • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma. (PubMed, Liver Cancer) - "HAIC was associated with lower rates of grade 3-4 TRAEs and TRAE-related discontinuation in both the overall population and the high-risk group. HAIC treatment provided superior survival benefits and a favorable safety profile compared to atezolizumab-bevacizumab in high-risk HCC patients."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes. (PubMed, Thorac Cancer) - "Adding bevacizumab to first-line ICI-chemotherapy did not enhance survival outcomes. Local treatment for BM did not provide additional survival advantages when combined with first-line ICI-based systemic therapy. Extracranial PD-L1 TPS ≥ 50% predicted improved intracranial efficacy."

IO biomarker • Journal • Real-world evidence • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer. (PubMed, J Exp Clin Cancer Res) - "Limiting BCAA intake not only suppresses tumor growth in KRAS-mutant CRC but also enhances the efficacy of the KRAS G12D inhibitor MRTX1133 and the monoclonal antibody bevacizumab. Our findings reveal a previously unknown regulatory mechanism of ECHS1 in CRC and offer new potential therapeutic targets."

Journal • Colorectal Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • KRAS

Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial. (PubMed, Med) - "Lamivudine, an oral inflammasome inhibitor, significantly improved vision in patients with CI-DME."

Clinical • Journal • Diabetic Macular Edema • Ophthalmology

Quality of life in patients with metastatic colorectal cancer receiving cytotoxic and cytotoxic plus targeted therapy. (PubMed, BMC Cancer) - "Compared with those on CyT alone, patients with mCRC receiving Cy-TaT showed improved overall H/QoL, functional scales, and symptom scales/items. These benefits were consistent across most subgroups of chemotherapy, with the greatest improvements in H/QoL observed in the CAPEOX-TaT and mFOLFOX-7-TaT groups."

HEOR • Journal • CNS Disorders • Colorectal Cancer • Fatigue • Insomnia • Oncology • Pulmonary Disease • Sleep Disorder • Solid Tumor

Intrahepatic Lymphoid Follicles Comprising T and B Cells Mimic Hepatocellular Carcinoma in a Hepatitis B Patient. (PubMed, Int J Mol Sci) - "Despite initial treatment with atezolizumab plus bevacizumab, the lesion progressed, leading to an extended left hepatectomy. The patient showed clinical and serologic improvement following corticosteroid therapy, with no evidence of recurrence at 10-month follow-up. This case underscores the importance of histopathological confirmation in hepatic masses with atypical features and highlights the need to consider benign immune-related mimickers in the differential diagnosis, particularly in the era of immunotherapy."

Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor • AFP

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment. (PubMed, Biomolecules) - "Furthermore, certain therapies (e.g., olaparib and bevacizumab) offer particularly pronounced benefits for high-grade serous ovarian cancer (HGSOC) patients harboring mutations in the DNA-binding domain (DBD) of BRCA1/2. A strong correlation between the HRD score and age was found. Our paper underlines the need to introduce other biological factors within the algorithms of the HRD evaluation in order to better tailor the HRD status, harmonize the metrics of the HRD assessment, and personalize therapies."

Journal • Real-world evidence • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

Management of Corneal Neovascularization With Diathermy and Intrastromal Bevacizumab Injection. (PubMed, Eye Contact Lens) - "Combined intrastromal injection of bevacizumab and FND is an effective treatment for corneal neovascularization."

Journal • Ophthalmology

Safety and Long-Term Efficacy of Intravitreal rtPA, Bevacizumab and SF6 Injection in Patients with Submacular Hemorrhage Secondary to Age-Related Macular Degeneration. (PubMed, J Clin Med) - " Triple injection constitutes a simple and effective therapy with long-term functional and anatomical improvements following treatment due to SMH, although patients have an increased risk for RPE tears. The 4-week postoperative VA following triple injection was predictive for long-term visual function."

Journal • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review. (PubMed, Children (Basel)) - "FMP targets that have been investigated in neuroblastoma include poly-ADP ribose polymerase (PARP) (targeted by PARPiFL), endothelial growth factor receptor (EGFR) (targeted by Panitumumab-IRDye800CW, Cetuximab-IRDye800CW, Nimotuzumab-IRDye800CW and QRHKPRE-Cy5), vascular endothelial growth factor receptor (VEGFR) (targeted by Bevacizumab IRDye800CW), and proteases such as cathepsins and matrix metalloproteinases that activate the fluorescent signal of FMPs, such as LUM015 and AVB-620. There are several clinically approved FMPs, or FMPs in clinical trials, that are used in adult oncology surgery that have targets expressed in neuroblastoma. Further research should validate these probes in neuroblastoma to enable their rapid translation into clinical practice."

Journal • Review • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • CTSS • EGFR • PARP1

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. (PubMed, J Neurooncol) - P2 | "We observed greater activity of bevacizumab against intracranial NVS compared to meningioma, evidenced by more favorable RR rates, durability of response, and rates of PD. Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation."

Journal • Brain Cancer • Genetic Disorders • Meningioma • Neurofibromatosis • Oncology • Solid Tumor

Adeno-Associated Virus-Engineered Umbilical Cord-Derived Mesenchymal Stromal Cells Overexpressing Human sFlt-1 for Anti-Angiogenesis. (PubMed, Life (Basel)) - "The anti-angiogenic potential of MSCs.hsFlt1 effectively demonstrated in this study suggests their promising utility for targeted anti-angiogenic gene therapy approaches."

Journal • Gene Therapies

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy. (PubMed, BMC Cancer) - "High-dose third-generation EGFR-TKIs combined with pemetrexed intrathecal chemotherapy demonstrated a high rate of intracranial symptom relief and manageable safety in patients with EGFRm NSCLC who developed leptomeningeal metastases after previous EGFR-TKI therapy."

Journal • Infectious Disease • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

REGTAS-2: Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - P3 | N=302 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Head-to-Head • New P3 trial • Colorectal Cancer • Oncology • Solid Tumor

Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer. (PubMed, Anticancer Res) - "The biweekly schedule of TAS-102 with/without bevacizumab was associated with a significantly lower incidence of grade ≥3 neutropenia than the standard schedule. This schedule may help patients - including those with impaired renal function - adhere to planned treatment regimens."

Journal • Retrospective data • Colorectal Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Early Access Program in oncology: Retrospective study at a Portuguese hospital (ECOP 2024) - "During the study period were submitted 163 EAP requests for abiraterone, amivantamab, bevacizumab, durvalumab, encorafenib, enfortumab, everolimus, erdafitinib, lenvatinib, lurbinectedin, niraparib, nivolumab, olaparib, pembrolizumab, pertuzumab, ramucirumab, sacituzumab govitecan, selpercatinib, trifluridine/tipiracil, trametinib+dabrafenib, trastuzumab-deruxtecan and tucatinib. Conclusion Most cases correspond to metastatic disease, EAPs facilitate timely access to innovative therapies for patients with high unmet medical needs. The majority of situations were financed, which confirms the importance of EAPs in an era where oncology is constantly innovating."

Retrospective data • Gastrointestinal Disorder • Oncology

Treatment Options for Alkali Burn-Induced Corneal Neovascularization: A Comparative Analysis of Two Tyrosine Kinase Inhibitors. (PubMed, Cornea) - "Axitinib reduced CNA and VLI, although not as effectively as other established treatment modalities, whereas dasatinib did not demonstrate significant effects."

Journal • Cataract • Ophthalmology • PECAM1

BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer (ESMO-GI 2025) - No abstract available

Clinical • Metastases • pMMR • Colorectal Cancer • Oncology • Solid Tumor

Resistance to Anti EGFR Through the Successive and Cumulative Acquisition of Two New Oncogenic Addictions: BRAF and ALK (ATS 2025) - "She received Gefitinib on the first line...Following progression on chemotherapy, the patient receives targeted therapies combining Dabrafenib, Trametinib and Osimertinib. Due to a dissociated response after 4 months of treatment, a 5th line of Paclitaxel Bevacizumab was initiated. Following a new progression and the presence of an ALK rearrangement on the re-biopsy, treatment with Alectinib was then proposed. The response was dissociated and a final line was therefore proposed before stopping active treatments for toxicity and deterioration in general condition. This case reports a resistance to anti-EGFR by the successive and cumulative acquisition of two new oncogene addictions and emphasizes the importance of rebiopsy at each progression on targeted therapy if feasible."

CNS Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Psychiatry • Solid Tumor • ALK • BRAF

Short-course radiotherapy followed by CAPOX combined with tislelizumab and bevacizumab or cetuximab for treatment-naive unresectable metastatic rectal cancer (UNION mRC). (ASCO 2025) - P3 | "Background: Doublet chemotherapy regimens based on oxaliplatin or irinotecan, combined with targeted agents such as bevacizumab or cetuximab, represent the standard first-line treatment for metastatic rectal cancer (mRC). Short-course radiotherapy followed by CAPOX combined with tislelizumab and bevacizumab or cetuximab showed encouraging efficacy and acceptable safety as first-line therapy for unresectable pMMR/MSS mRC. These results support further studies to confirm the benefits of this treatment strategy."

IO biomarker • Metastases • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor • BRAF • MSI